Navigation Links
Data Presented For ENMD-2076 In Xenograft Models Of Human Hepatocellular Carcinoma
Date:10/22/2013

ROCKVILLE, Md., Oct. 22, 2013 /PRNewswire/ -- EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced today the presentation of preclinical data for a study comparing the efficacy of ENMD-2076 against that of standard of care agents including sorafenib, doxorubicin, and 5-FU for human hepatocellular carcinoma (HCC) models.  The results of the study were presented at AACR-NCI-EORTC International Conference being held this week in Boston, Massachusetts.

(Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO )

The data presented demonstrate significant in vivo activity of ENMD-2076 against three different human hepatocellular carcinoma xenograft models and concluded that ENMD-2076 showed robust antitumor activity against the cell line-derived xenograft models of human HCC superior to that of sorafenib, doxorubicin, and 5-FU.

Ken K. Ren, Ph.D., EntreMed's Chief Executive Officer, commented, "HCC represents the third leading cause of cancer deaths worldwide.  There are unmet medical needs for drugs with better safety and efficacy.  This in vivo preclinical study data is affirmative with our previous in vitro findings that greater than 60% of 21 liver cancer-derived cell lines we screened are significantly inhibited by ENMD-2076 treatment.  It also indicates that ENMD-2076 may be effective in patients resistant to sorafenib or 5-FU.  In our Phase 1 trial of ENMD-2076, partial response with prolonged progression free survival was observed in a patient with liver cancer who relapsed from standard care including liver transplantation and sorafenib treatment. This preclinical study provides support for further clinical investigation of the drug candidate in
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
2. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
3. Worldwide Multicenter Experiences with CardioFocus HeartLight® EAS to be Presented at Heart Rhythm 2012
4. Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV
5. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
6. eCardios CEO to Speak During "Act at the Speed of Opportunity" Event Presented by Comcast Business Class and Inc.
7. CutisPharma Homogeneity and Stability Study for Mouthwash Compounding Kits Presented at NERDG Meeting
8. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
9. Webcast Alert: Isis Pharmaceuticals Hosts Dr. Sotirios Tsimikas to Review KYNAMRO™ data Presented at the European Atherosclerosis Society 2012 Meeting
10. Body Monitors Deliver Better Weight Loss Results at Half the Cost: Study to Be Presented at ACSM Meeting
11. CyberKnife® Prostate SBRT Outcomes and Quality of Life Data Presented at American Urological Association Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , September 17, 2014 According ... by Component (Sensor, Battery, Memory Device, Display, & Microprocessor/MCU), ... & Wellness), and by Geography - Global Forecast to ... electronics market is expected to reach $56.50 Billion by ... to 2020. Browse 235 market data Tables ...
(Date:9/17/2014)... -- Women everywhere know how frustrating a vaginal infection ... often also embarrassing and have a way of derailing ... http://ph-defense.com ) is a new, over-the-counter product designed to ... Odor, discharge, and discomfort or itch ... many cases, the cause of such problems can be ...
(Date:9/17/2014)... LEIPZIG, Germany , Sept. 17, ... has entered into an exclusive technology development partnership ... imaging agents to image CD4+ positive immune T ... ImaginAb,s capability to precisely diagnose and determine therapeutic ... areas. The ability to image CD4+ T-cells will ...
Breaking Medicine Technology:Medical Electronics Market Worth $56.50 Billion by 2020 2Medical Electronics Market Worth $56.50 Billion by 2020 3Medical Electronics Market Worth $56.50 Billion by 2020 4New Product from Vireo Systems: pH-D Feminine Health Support 2ImaginAb Expands ImmunoPET Pipeline to Include CD4+ T-Cell Imaging 2
... , , , ... service Contract Research Organization (CRO) founded in India, today announced the ... Application Suite (OLSAS) by going live with Oracle Siebel Clinical Trial ... , "We are excited to have the rollout of ...
... Aug. 5 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: ... a New Drug Submission (NDS) with the Therapeutic Products ... the antidepressant trazodone. , "We are pleased to file ... R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. ...
Cached Medicine Technology:SIRO Clinpharm Completes Successful Implementation of Oracle Life Sciences Application Suite 2Labopharm files New Drug Submission with Health Canada for novel antidepressant 2Labopharm files New Drug Submission with Health Canada for novel antidepressant 3
(Date:9/17/2014)... Recently, UWDress.com, an innovative company that provides many kinds ... released its 2014 empire waist evening dress ... big sale for these new and beautiful products. All ... from 15 to 65 percent off. , It ... to wear materials. Its elegant items include gold empire ...
(Date:9/17/2014)... 2014 According to Centers for ... an estimated 173,285 sports- and recreation-related traumatic brain injuries, ... a blood test may be available to help doctors ... recovery will take. , In March of this ... found a way to test blood for a protein ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 According ... Drug Administration report titled “Adverse Events Associated with ... a Dermal Filler,” unapproved use of Expression, a ... resulted in adverse reactions including discoloration, lumps, bruising, ... with FDA approval for cosmetic use include ...
(Date:9/17/2014)... Final Cut Pro X plugin developers have ... Pixel Film Studios. , “ProBlue 5k is a compilation of ... to epic,” said Christina Austin, CEO of Pixel Film Studios. ... a definite game changer.” , ProBlue 5k is the ultimate ... filmmaker ! This footage compilation of over 100 anamorphic flares ...
(Date:9/17/2014)... struggle to distinguish between a business strategy and business plan, ... answer by reading Per Wickstrom’s latest blog post. , “The ... and a business strategy are both strategic – and what’s ... view it is that a business plan is part one, ... , According to the blog post, a business plan is ...
Breaking Medicine News(10 mins):Health News:2014 Empire Waist Evening Dress Collection Now Unveiled At UWDress.com 2Health News:Breakthrough blood test will improve concussion diagnoses, treatment 2Health News:Breakthrough blood test will improve concussion diagnoses, treatment 3Health News:Simon Ourian, Kim Kardashian's Cosmetic Surgeon, Warns About Illegal Use of Expression as a Dermal Filler 2Health News:A New Plugin Entitled ProBlue 5k Was Released Today from Pixel Film Studios Exclusively for Final Cut Pro X 2Health News:Per Wickstrom’s Latest Blog Explores the Difference Between a Business Plan and a Business Strategy 2
... the Eye ... Americans at Great Risk, PINELLAS PARK, Fla., Nov. 12 ... largely unaware of,the dangers that extended exposure to harmful ultraviolet (UV) ... England Eye Institute,and Transitions Optical, found that while nearly 80 percent ...
... November 12 Schlafender Hase GmbH,today released the ... The Text Verification Tool is a patent-protected ... print layout ("artwork") on the data,level - independent ... may be annotated, saved in PDF format and ...
... with prostate cancer are at greater risk of death after ... 2007 issue of CANCER, a peer-reviewed journal of the American ... Massachusetts General Hospital in Boston and colleagues, found that a ... diagnosis was an independent risk factor for prostate cancer-related death. ...
... We Are" (p. 42). "There was at,the end of 1968 ... For the Sixties were also the glory years of the ... writes former,NBC News anchor Tom Brokaw, in his forthcoming book, ... which Newsweek looks back at,one of the defining years of ...
... in Washington D.C., North Texas, Los Angeles, and ... Chicago, Effort latest in long K of C tradition ... ... distributed a total of $1 million worth of wheelchairs to veterans,in need at four locations on ...
... of the same,family, who owned and operated a ... Comprehensive Outpatient Rehabilitation Facilities have,each been sentenced to ... General Alice S. Fisher of the Criminal Division ... District of Florida announced today., Carlos Berenguer, ...
Cached Medicine News:Health News:Survey Confirms Americans Have a True 'Blind Spot' Regarding Their Eye Health - and the Real Danger of UV Rays 2Health News:Survey Confirms Americans Have a True 'Blind Spot' Regarding Their Eye Health - and the Real Danger of UV Rays 3Health News:Survey Confirms Americans Have a True 'Blind Spot' Regarding Their Eye Health - and the Real Danger of UV Rays 4Health News:Schlafender Hase Releases Text Verification Tool 4.0 2Health News:Obesity and overweight linked to higher prostate cancer mortality 2Health News:NEWSWEEK: Media Lead Sheet/November 19, 2007 Issue (on newsstands Monday, November 12) 2Health News:NEWSWEEK: Media Lead Sheet/November 19, 2007 Issue (on newsstands Monday, November 12) 3Health News:NEWSWEEK: Media Lead Sheet/November 19, 2007 Issue (on newsstands Monday, November 12) 4Health News:NEWSWEEK: Media Lead Sheet/November 19, 2007 Issue (on newsstands Monday, November 12) 5Health News:Knights Distribute $1 Million Worth of Wheelchairs to Veterans 2Health News:Four Miami Health Care Company Owners Sentenced to 57 Months in Prison For Medicare Fraud 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: